Key result
Tolbutamide infusion increases acute insulin response to isoproterenol and arginine by ~50%.
Why the study?
The effect of tolbutamide on insulin release to nonglucose stimuli in non-insulin-dependent diabetes mellitus and the modulation by plasma glucose levels were unclear.
Does tolbutamide infusion increase the acute insulin response to nonglucose stimuli in male subjects with non-insulin-dependent diabetes mellitus?
Does tolbutamide infusion increase the acute insulin response to nonglucose stimuli in male subjects with non-insulin-dependent diabetes mellitus?
Tolbutamide augments the acute insulin response to nonglucose stimuli in NIDDM, an effect that is partially blunted by the concomitant decrease in plasma glucose.
Answers are grounded in this paper and cite their sources.
Should not alter sulfonylurea prescribing in type 2 diabetes; leaves open mechanisms and durability of augmented insulin responses.
To determine the effect of tolbutamide on insulin release to nonglucose stimuli in non-insulin-dependent diabetes mellitus and how plasma glucose levels may modulate this effect, the acute insulin response (AIR) to an isoproterenol (12 Micrograms) or an arginine (5 g) i.v. pulse was determined before and during a tolbutamide infusion (7.5 mg/m2/min) in 25 male subjects. During the tolbutamide infusion, there was an increase in the AIR to both isoproterenol (% delta AIR = +49 +/- 21%, N = 11, P less than 0.05) and arginine (% delta AIR = +52 +/- 15%, N = 12, P less than 0.005) and a decrease in plasma glucose (delta plasma glucose for isoproterenol = -24 +/- 6 mg/dl, P less than 0.005; for arginine = -26 +/- 3 mg/dl, P less than 0.001). In separate studies, when the plasma glucose was clamped at baseline values by a variable rate of glucose infusion, there was a greater effect of tolbutamide on AIR when compared with the unclamped tolbutamide studies (isoproterenol: % delta AIR = +132 +/- 25%, P less than 0.025; arginine: % delta AIR = +95 +/- 12%, P less than 0.05). Thus, tolbutamide increases the AIR of nonglucose stimuli, but this augmentation by tolbutamide is blunted by the concomitant decrease in plasma glucose. Consideration of this observation is necessary when interpretating the effects of a sulfonylurea on islet cell responses.
No takes yet. Share an insight, caveat, or question.
Pfeifer et al. (1982) studied Non-insulin-dependent diabetes mellitus (n=25). Tolbutamide vs. Baseline was evaluated on Acute insulin response (AIR) to nonglucose stimuli (isoproterenol or arginine) (% delta AIR +49% (isoproterenol) and +52% (arginine), p=<0.05). Tolbutamide infusion increased the acute insulin response to isoproterenol (+49%, P<0.05) and arginine (+52%, P<0.005), which was further augmented when glucose was clamped.
Synapse has enriched 10 related papers. Consider them for comparative context: